Our study not only identified novel downstream phosphorylation substrates of BCKDK but also elucidated the critical role of the BCKDK/AKT axis in RCC progression, providing a potential therapeutic target for clinical intervention in cancer. Here, AKT1 is linked to renal cell carcinoma.